Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
03 janv. 2022 06h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Completes Exit from Laboratory Business with Sale of Affiliate Lab
20 déc. 2021 16h05 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
New Study Shows Patients With Irritable Bowel Syndrome and Functional Dyspepsia Experience High Levels of Bloating and Distension
09 déc. 2021 09h00 HE
|
Rome Foundation
RALEIGH, N.C., Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Rome Foundation Research Institute and Danone Nutricia Research have partnered on a study to look at the prevalence of bloating and distension in...
Sonic Incytes Medical Corp. Successfully Completes Series A Raise of US$7.3M to Accelerate Velacur™ Commercialization
07 déc. 2021 10h00 HE
|
Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M...
Progenity Announces New Patent for Single-Molecule Detection Technology
02 déc. 2021 06h30 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today announced a...
Rome Foundation Releases Clinical Criteria to Better Meet Needs of Patients
29 nov. 2021 09h00 HE
|
Rome Foundation
RALEIGH, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- The Rome Foundation has published a groundbreaking modification of the Rome IV diagnostic criteria of the Disorders of Gut Brain Interaction (DGBI -...
Progenity Strengthens its Liquidity Position
23 nov. 2021 06h30 HE
|
Progenity, Inc.
Company received more than $44 million in warrant exercises since August 2021. Current liquidity position provides runway to achieve critical research and development milestones through 2022. SAN...
Progenity to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
15 nov. 2021 06h30 HE
|
Progenity, Inc.
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that the company will participate in a pre-recorded fireside chat at...
Velacur™ Data Presented at 2021 AASLD The Liver Meeting®
12 nov. 2021 08h00 HE
|
Sonic Incytes Medical Corp.
VANCOUVER, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first handheld 3D liver health...
Progenity Provides Corporate Update and Reports Third Quarter 2021 Financial Results
10 nov. 2021 16h01 HE
|
Progenity, Inc.
Added important patents further protecting the company’s therapeutic delivery technologiesAdded strong biotherapeutics capabilities to management team and board of directorsImplemented cost-cutting...